About us

In addition to patient care at the highest level in the main areas of oncology and pneumology, our department is characterized by intensive and internationally recognized research activity in the field of cancer research. For our medical colleagues, we are a reliable partner in the joint treatment of our patients.

I would like to welcome you to the website of the Department of Internal Medicine VIII (Division of Medical Oncology and Pneumology) of the Medical Clinic of the University Hospital of Tübingen.

The focus of our work in the field of medical oncology is the treatment of patients with solid tumor diseases, which also includes novel approaches to personalized oncology/precision oncology of patients with advanced tumor diseases. For this purpose, our outpatient therapy area and a specially equipped Phase I ward / Early Clinical Trial Unit (ECTU) are available, in which we can offer our patients not only all standard therapies but also novel, as yet unapproved therapeutic modalities. We have further special oncological focuses in the area of sarcomas (the Tübingen Center for Soft Tissue Sarcomas, GIST and Bone Tumors (ZWS) is one of the largest of its kind in Germany) as well as theof its kind in Germany) and neuroendocrine tumors (the NET Center Tübingen was certified as a Center of Excellence (CoE) by the European Neuroendocrine Tumor Society (ENETS) in 2021).

In addition to diagnostics and personalized therapy of all lung tumors, our focus in the field of pneumology includes comprehensive pneumological differential diagnostics as well as weaning and adjustment to non-invasive home ventilation (NIV).

In addition to patient care at the highest level, our department is characterized by intensive and internationally recognized research activity, which includes both the field of cancer research and pneumology.

For our medical colleagues, we are a reliable and always easily accessible partner in the joint treatment of our patients.

We hope that the references and information on the following pages will give you an overview of the various areas of the clinic, the extensive range of patient care services, our main areas of research and current events.

With best regards
Univ.Prof. Dr. Lars Zender

Health Care


Our specialties include all forms of soft tissue sarcomas, bone tumors, gastrointestinal stromal tumors (GIST), neuroendocrine neoplasms (NEN tumors), NUT carcinomas, and other solid tumor diseases.

Oncology area
Molecular Diagnostics as a Science Concept


Personalized oncology determines which individual changes are present in the cancer cells of each patient and aligns individual targeted therapies (in the sense of precision oncology).

Learn more


Our main areas of expertise are pneumological oncology, interventional bronchology as well as ventilation and weaning. We have a wide range of procedures available for pneumological differential diagnostics.

Pneumology area
Professor at the patient's bedside

Phase I Clinic

Patients with advanced tumor diseases are treated with new cancer therapies in our outpatient therapy area and on our specially equipped Phase I ward.

Phase I Clinic

Patient registration

For emergencies

please call our emergency department directly:

+49 7071 29-82090


Outpatient Clinic for Neuroendocrine Tumors / NET Outpatient Clinic

Mon - Thurs from 8 a.m. - 3.30 p.m.
Fri from 8 a.m. - 2 p.m.

Medical Clinic,
Otfried-Müller-Str. 10,
Building 500, Level 06, Ward 76

+49 7071 29-83132

+49 7071 29-25242


Inpatient admission

Ulrike Howahl

+49 7071 29-87268

Sandra Mayer

+49 7071 29-84330

+49 7071 29-4475


Referring clinics and practices


Through close collaboration between cancer researchers and physicians, we develop new treatment options for previously untreatable tumor diseases and make them available to our patients as quickly as possible. In addition to clinical trials on NET tumor therapy, we conduct basic research on immunotherapy and virotherapy of neuroendocrine tumors and target identification for novel molecular therapies in NET tumors.


Press releases

Show all press releases

Other current topics

Europe visits Tübingen for the CIVIS Summer School on Cancer Immunotherapy

"Basics & Translational Approaches in Immunotherapy of Cancer", more than 30 students and more than 10 lecturers from many European countries gathered at the University Hospital Tübingen from 20.06.2022 - 24.06.2022 under the direction of Prof. Lauer (Dept. of Medical Oncology; Internal Medicine VIII (Medical Directorro: Prof. Zender)). The attached film gives an overview of the activities of this Summer School in particular, but also of other Summer Schools that were subsequently organized in Tübingen on other topics.

Older posts:

DFG approves Cluster of Excellence "Individualization of Tumor Therapies by Molecular Imaging and Functional Identification of Therapeutic Targets (iFIT)".

Learn more

The Abendzeitung München (AZ München) dedicates a whole page to virotherapy in its issue of 12.6.2017 under its column "München-Medizin". This article begins with the words "...Orthodox medicine has (re)discovered viruses as helpers against cancer. There are no sensational reports yet. But interesting is the research already now ...". The remainder of the article provides an up-to-date overview of the state of virotherapy research in the laboratory and in its application for cancer patients. In addition, the interplay of virus and infected tumor cell/infected organism is specifically highlighted.


PDF Download

Immunotherapeutic procedures have led to major improvements in cancer treatment. In particular, so-called immune checkpoint modulators (ICMs) have contributed to this: the active ingredients ipilimumab, nivolumab, pembrolizumab or atezolizumab are now approved for a number of cancers; further indications as well as the approval of additional ICM immunotherapeutics will follow in the near future.

In addition, there are many other novel immunotherapy strategies currently being evaluated in clinical trials that open up completely new perspectives.

These include, in particular, virotherapeutics containing infectious viral particles capable of preferentially infecting tumor cells. In the course of the production of thousands of progeny viruses, the infected tumor cells are dissolved (so-called tumor cell lysis or oncolysis). The sudden, simultaneous release of viral and tumor cell components leads to a strong and sustained stimulation of the immune system, enabling tumor foci to be fought everywhere in the body.

In the following interview with Prof. Lauer, the current state of development of these virotherapeutics is presented and discussed.

PDF Download

Certificates and Associations